INTRODUCTION
============

Hepatocyte growth factor (HGF) was discovered in 1984,^[@r01]^ purified and isolated in 1986,^[@r02],[@r03]^ and first characterized as a strong mitogen for hepatocytes. It is produced in a number of organs and is now known to be a multifunctional factor with various biological activities.^[@r04]--[@r06]^ HGF was found to be elevated in serum from patients with liver disease and cancer, including those with malignancies of the breast,^[@r07]^ stomach,^[@r08],[@r09]^ colorectum,^[@r10]^ and lung.^[@r11]^ Furthermore, HGF was inversely correlated with survival time in cancer patients,^[@r12]^ which indicates that it might be a prognostic marker in such patients.^[@r10],[@r13]^ However, existing reports are limited to patients with diagnosed cancer. Thus, we examined whether serum HGF was a predictor of cancer death among apparently healthy Japanese living in the general community.

METHODS
=======

A periodic epidemiologic survey was performed in 1999 in the small farming community of Tanushimaru, Japan. As reported previously, the demographic characteristics of the residents of this area are similar to those of the general Japanese population.^[@r14]^ A total of 1492 adults aged 40 years or older underwent health check-ups, and a questionnaire was used to ascertain their medical history (particularly cancer), use of alcohol, smoking, and current use of medications for hypertension, hyperlipidemia, and diabetes. Alcohol intake and smoking were classified as current habitual use or not. Use of medication for hypertension, hyperlipidemia, and diabetes was coded as dummy variables. Body mass index (BMI) was calculated from measurements of height and body weight. Blood pressure was measured twice with participants in the supine position. A second blood pressure reading was taken after 5 deep breaths, and the fifth-phase diastolic pressure was recorded and used in the analysis. Blood samples obtained from the antecubital vein were centrifuged and frozen. Using these samples, we measured serum glycosylated hemoglobin A1c (Japan Diabetes Society; HbA1c \[JDS\]), lipids (total cholesterol, high-density lipoprotein \[HDL\]-cholesterol, and triglycerides), blood urea nitrogen (BUN), creatinine, uric acid, albumin, C-reactive protein (CRP), and liver enzymes (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], and γ-glutamyl transpeptidase \[γ-GTP\]). Plasma HGF was measured by enzyme-linked immunosorbent assay (ELISA).^[@r15]^ Intra- and inter-assay coefficients of variation of HGF, as determined by a commercially available laboratory (Kyodo Igaku Laboratory, Fukuoka, Japan), were 1.0% and 3.0%, respectively. The details of HGF measurement have been previously described.^[@r16]^ Twenty-four participants who had a history of liver disease, lung disease, or cancer were excluded from the analysis. Ultimately, 1470 participants (595 men and 875 women) were enrolled.

The follow-up period was 10 years. Cause of death was determined on the basis of a review of obituaries, medical records, death certificates, and hospital charts, as well as interviews with primary care physicians, the families of the deceased, and other witnesses. Because many patients with cancer ultimately die from infection or other illnesses, great care was taken to identify underlying cause of death. The information was coded independently according to the rules of the Seven Countries Study^[@r17]^ and the World Health Organization's 10th Revision of the International Statistical Classification of Diseases and Related Health Problems (WHO-ICD).^[@r18]^ Follow-up data through the end of March 2010 were analyzed. The follow-up rate was 92.9%.

This study was approved by the Ukiha Branch of the Japan Medical Association, by the local citizens' committee of Tanushimaru, and by the Ethics Committee of Kurume University. All participants gave informed consent.

Statistical analysis
--------------------

Results are presented as mean ± SD. Because of skewed distributions, natural logarithmic transformations were performed for CRP, triglycerides, and γ-GTP. These variables are shown in the original scale in the tables, after analysis using the log (natural)-transformed values. In Tables [1](#tbl01){ref-type="table"} and [2](#tbl02){ref-type="table"}, the values for CRP, triglycerides, and γ-GTP are presented as geometric mean and range.

###### Characteristics of participants by quartile of HGF

  Variables                       Quartile of HGF level   *P* for trend^a^                                                                                            
  ------------------------------- ----------------------- ------------------ ------------- ----- ---- ------------- ----- ---- ------------- ----- ---- ------------- ----------
  Total No.                       349                     24                               397   27                 341   23                 383   26                  
  No. and % of deaths             25                      7                                36    9                  49    14                 59    15                 0.001
  HGF, ng/ml                                                                 0.14 (0.02)              0.19 (0.01)              0.24 (0.02)              0.35 (0.08)    
  Age, years                                                                 62 (10)                  63 (11)                  63 (11)                  63 (11)       0.397
  Male sex                        93                      27                               154   39                 155   45                 193   50                 \<0.0001
  Body mass index^b^                                                         22 (3)                   23 (3)                   23 (3)                   24 (3)        \<0.0001
  Systolic BP, mm Hg                                                         131 (21)                 132 (20)                 136 (21)                 136 (22)      0.001
  Diastolic BP, mm Hg                                                        78 (11)                  78 (11)                  80 (12)                  80 (12)       0.034
  HbA1c, %                                                                   5.2 (0.7)                5.2 (0.7)                5.3 (0.7)                5.3 (0.9)     0.103
  Blood urea nitrogen, mmol/l                                                5.9 (1.5)                5.7 (1.4)                5.9 (1.5)                5.8 (1.5)     0.323
  Creatinine, µmol/l                                                         73 (15)                  74 (14)                  77 (19)                  78 (17)       \<0.0001
  Uric acid, µmol/l                                                          268 (71)                 292 (83)                 303 (89)                 303 (83)      \<0.0001
  C-reactive protein^c^, mg/dl                                               0.17                     0.18                     0.19                     0.23          \<0.0001
   Range                                                                     0.1--3.9                 0.1--3.9                 0.1--3.9                 0.1--11.5      
  Albumin, g/l                                                               44 (2)                   44 (2)                   44 (3)                   44 (3)        0.546
  Total cholesterol, mmol/l                                                  5.3 (0.9)                5.2 (0.9)                5.3 (1.0)                5.0 (0.9)     \<0.001
  HDL cholesterol, mmol/l                                                    1.5 (0.4)                1.5 (0.3)                1.5 (0.4)                1.4 (0.4)     \<0.0001
  Triglycerides^c^, mmol/l                                                   0.99                     1.08                     1.13                     1.20          \<0.0001
   Range                                                                     0.33--7.29               0.33--10.9               0.41--13.5               0.32--14.5     
  AST, units/l                                                               27 (4)                   28 (4)                   28 (6)                   29 (6)        0.010
  ALT, units/l                                                               26 (3)                   26 (3)                   26 (3)                   27 (4)        0.049
  γ-GTP^c^, units/l                                                          15                       18                       20                       23            \<0.0001
   Range                                                                     1--201                   1--218                   3--896                   3--305         
  Smoking                         30                      9                                52    13                 69    20                 87    23                 \<0.0001
  Alcohol                         61                      17                               90    23                 74    22                 85    22                 0.297
  Antihypertensive medication     51                      15                               72    18                 71    21                 89    23                 0.022
  Antihyperlipidemic medication   18                      5                                21    5                  19    6                  14    4                  0.619
  Antidiabetic medication         6                       2                                11    3                  8     2                  15    4                  0.311

Data are mean (SD), geometric mean, range, or percent.

Abbreviations: HGF, hepatocyte growth factor; SD, standard deviation; BP, blood pressure; HbA1c, glycosylated hemoglobin A1c; HDL, high-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase.

^a^Calculated from linear regression analysis for continuous variables and from logistic regression analysis for dichotomous variables.

^b^Weight (kg)/height (m)^2^.

^c^These variables are shown in the original scale after analysis using log (natural)-transformed values.

###### Characteristics of participants stratified by vital status

  Variables                       Survivors   Decedents   *P* value                              
  ------------------------------- ----------- ----------- ------------- ----- ---- ------------- ----------
  Total No.                       1291        88                        169   12                  
  HGF, ng/ml                                              0.23 (0.09)              0.26 (0.11)   0.009
  Age, years                                              61 (10)                  72 (9)        \<0.0001
  Male sex                        487         38                        103   61                 \<0.0001
  Body mass index^a^                                      23 (3)                   22 (3)        0.016
  Systolic BP, mm Hg                                      132 (20)                 144 (24)      \<0.0001
  Diastolic BP, mm Hg                                     79 (11)                  81 (12)       0.056
  HbA1c, %                                                5.2 (0.7)                5.4 (1.2)     0.033
  Blood urea nitrogen, mmol/l                             5.7 (1.4)                6.4 (1.9)     \<0.0001
  Creatinine, µmol/l                                      74 (15)                  85 (22)       \<0.0001
  Uric acid, µmol/l                                       286 (83)                 321 (89)      \<0.0001
  C-reactive protein^b^, mg/dl                            0.19                     0.22          0.0004
   Range                                                  0.1--11.5                0.1--5.2       
  Albumin, g/l                                            44 (2)                   42 (3)        \<0.0001
  Total cholesterol, mmol/l                               5.2 (0.9)                4.9 (0.9)     \<0.0001
  HDL cholesterol, mmol/l                                 1.5 (0.4)                1.5 (0.4)     0.485
  Triglycerides^b^, mmol/l                                1.10                     1.09          0.837
   Range                                                  0.32--14.4               0.34--4.73     
  AST, units/l                                            28 (5)                   28 (6)        0.485
  ALT, units/l                                            26 (4)                   26 (3)        0.460
  γ-GTP^b^, units/l                                       18                       22            0.043
   Range                                                  1--310                   3--896         
  Smoking                         187         15                        47    28                 \<0.0001
  Alcohol                         268         21                        40    24                 0.429
  Antihypertensive medication     234         18                        48    28                 0.02
  Antihyperlipidemic medication   60          5                         12    7                  0.228
  Antidiabetic medication         32          2                         8     5                  0.148

Data are mean (SD), geometric mean, range, or percent.

Abbreviations: HGF, hepatocyte growth factor; SD, standard deviation; BP, blood pressure; HbA1c, glycosylated hemoglobin A1c; HDL, high density lipoprotein; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase.

^a^Weight (kg)/height (m)^2^.

^b^These variables are shown in the original scale after analysis using log (natural)-transformed values.

Mean HGF level was classified into quartiles as follows: ≤0.16 ng/ml, 0.17--0.21 ng/ml, 0.22--0.27 ng/ml, and ≥0.28 ng/ml. Analysis of variance was used to compare the means of variables, stratified by quartile of HGF levels. Differences between the 2 groups (survivors vs decedents) were assessed using the *t* test. The χ^2^ test was used to test differences between groups in categorical variables.

Multivariate proportional hazards regression was used to estimate the predictive HGF level for all-cause death and cancer death. We estimated hazard ratios (HRs) and their 95% CIs per 1-unit (approximately 1 SD) increase in the variable. Survival curves for all-cause death and cancer death for each HGF quartile were estimated with the Kaplan-Meier method and interpreted using the log-rank statistic. Statistical significance was defined as a *P* value less than 0.05. All statistical analyses were performed using SAS software (Release 9.2, SAS Institute, Cary, NC, USA).

RESULTS
=======

Baseline characteristics associated with HGF
--------------------------------------------

Participants were divided into quartiles according to HGF level. There was a significant positive association between HGF and mortality. In addition, HGF was significantly positively associated with male sex, BMI, systolic and diastolic blood pressures, creatinine, uric acid, CRP, triglycerides, AST, ALT, γ-GTP, smoking, and use of antihypertensive medication and significantly inversely associated with total cholesterol and HDL cholesterol (Table [1](#tbl01){ref-type="table"}).

Cause of death and characteristics of decedents
-----------------------------------------------

We were able to ascertain cause of death for 92.9% of deaths. There were 169 (103 men and 66 women) deaths: 61 (36.1%) from cancer, 32 (18.9%) from cerebrocardiovascular disease, 27 (16.0%) from infection, and 49 (29.0%) from other causes.

Table [2](#tbl02){ref-type="table"} shows the characteristics of participants stratified by vital status. Factors positively associated with death were age, male sex, systolic blood pressure, HbA1c, BUN, creatinine, uric acid, CRP, γ-GTP, smoking, use of antihypertensive medication, and HGF, whereas BMI, albumin, and total cholesterol were inversely associated with death.

Regression coefficients for all-cause death in the univariate proportional hazards regression model are shown in Table [3](#tbl03){ref-type="table"}. Age, male sex, systolic blood pressure, HbA1c, BUN, creatinine, uric acid, CRP, γ-GTP, smoking, antihypertensive medication, and HGF were significant positive predictors of all-cause death, whereas BMI, albumin, and total cholesterol were inversely associated with all-cause death. Figure [1](#fig01){ref-type="fig"}A shows the cumulative survival curves for all-cause death stratified by HGF quartile in univariate analysis. The HRs by HGF quartile were 1.30 (95% CI, 0.77--2.22) for Q2, 2.18 (1.31--3.62) for Q3, and 2.41 (1.47--3.94) for Q4. Cancer death was positively associated with age, male sex, systolic blood pressure, HbA1c, BUN, creatinine, and smoking and inversely associated with albumin and total cholesterol (Table [4](#tbl04){ref-type="table"}). Figure [1](#fig01){ref-type="fig"}B shows the cumulative survival curves for cancer death stratified by HGF quartile in univariate analysis. Mortality increased in relation to HGF (log-rank test = 11.3; *P* \< 0.001). The HRs by HGF quartile were 1.39 (95% CI, 0.60--3.26) for Q2, 1.39 (0.58--3.35) for Q3, and 2.72 (1.25--5.92) for Q4. For cancer death, mortality increased in relation to HGF (log rank test = 8.23; *P* = 0.03).

![(A) Kaplan-Meier survival curves for all-cause death, stratified by quartile of hepatocyte growth factor (HGF), after adjustment for age and sex. (B) Kaplan-Meier survival curves for cancer death, stratified by quartile of hepatocyte growth factor (HGF), after adjustment for age and sex.](je-22-395-g001){#fig01}

###### Univariate regression coefficients for all-cause death from a Cox proportional hazards regression model

  Variable (increment)                Beta     SE      Hazard ratio   95% CI       *P* value
  ----------------------------------- -------- ------- -------------- ------------ -----------
  HGF (0.09 ng/ml)                    3.271    0.721   1.35           1.19, 1.54   \<0.0001
  Age (10 years)                      0.103    0.008   2.95           2.49, 3.49   \<0.0001
  Male sex                            0.835    0.185   2.31           1.60, 3.32   \<0.0001
  Body mass index^a^ (3 kg/m^2^)      −0.067   0.025   0.81           0.69, 0.95   0.009
  Systolic BP (20 mm Hg)              0.021    0.003   1.57           1.38, 1.79   \<0.0001
  Diastolic BP (11 mm Hg)             0.012    0.006   1.15           0.99, 1.34   0.060
  HbA1c (0.7%)                        0.210    0.069   1.18           1.06, 1.31   0.002
  Blood urea nitrogen (1.4 mmol/l)    0.089    0.016   1.44           1.26, 1.65   \<0.0001
  Creatinine (16.4 µmol/l)            1.452    0.168   1.30           1.22, 1.38   \<0.0001
  Uric acid (59.4 µmol/l)             0.244    0.050   1.40           1.22, 1.61   \<0.0001
  C-reactive protein^b^ (1.8 times)   0.328    0.104   1.39           1.13, 1.70   0.002
  Albumin (2 g/l)                     −2.253   0.268   0.56           0.49, 0.64   \<0.0001
  Total cholesterol (0.87 mmol/l)     −0.011   0.002   0.68           0.58, 0.80   \<0.0001
  HDL cholesterol (0.36 mmol/l)       −0.003   0.005   0.99           0.82, 1.11   0.557
  Triglycerides^b^ (1.1 times)        −0.038   0.153   0.96           0.71, 1.30   0.804
  AST (5 units/l)                     0.011    0.014   1.06           0.91, 1.24   0.447
  ALT (3 units/l)                     −0.020   0.027   0.93           0.77, 1.13   0.463
  γ-GTP^b^ (2.2 times)                0.224    0.102   1.25           1.03, 1.53   0.030
  Smoking                             0.785    0.172   2.19           1.57, 3.07   \<0.0001
  Alcohol                             0.172    0.181   1.19           0.83, 1.69   0.341
  Antihypertensive medication         0.545    0.170   1.73           1.23, 2.41   0.001
  Antihyperlipidemic medication       0.428    0.299   1.54           0.85, 2.76   0.152
  Antidiabetic medication             0.592    0.362   1.81           0.89, 3.68   0.102

Abbreviations: HGF, hepatocyte growth factor; BP, blood pressure; HDL, high-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase.

^a^Weight (kg)/height (m)^2^.

^b^These variables are shown in the original scale after analysis using log (natural)-transformed values. These values indicate hazard ratios per times increase.

###### Univariate regression coefficients for cancer death from a Cox proportional hazards regression model

  Dependent variable (increment)      Beta     SE      Hazard ratio^c^   95% CI       *P* value
  ----------------------------------- -------- ------- ----------------- ------------ -----------
  HGF (0.09 ng/ml)                    3.949    1.185   1.44              1.16, 1.78   \<0.001
  Age (10 years)                      0.072    0.013   2.14              1.62, 2.82   \<0.0001
  Male sex                            0.919    0.295   2.51              1.41, 4.47   0.001
  Body mass index^a^ (3 kg/m^2^)      −0.005   0.042   0.98              0.76, 1.27   0.894
  Systolic BP (20 mm Hg)              0.013    0.005   1.31              1.04, 1.66   0.024
  Diastolic BP (11 mm Hg)             0.009    0.011   1.11              0.87, 1.43   0.413
  HbA1c (0.7%)                        0.280    0.100   1.24              1.07, 1.45   0.005
  Blood urea nitrogen (1.4 mmol/l)    0.058    0.029   1.27              1.01, 1.61   0.044
  Creatinine (16.4 µmol/l)            1.042    0.409   2.84              1.27, 6.32   0.011
  Uric acid (59.4 µmol/l)             0.101    0.090   1.15              0.90, 1.47   0.259
  C-reactive protein^b^ (1.8 times)   0.320    0.174   1.38              0.98, 1.94   0.066
  Albumin (2 g/l)                     −1.828   0.471   0.63              0.49, 0.79   \<0.001
  Total cholesterol (0.87 mmol/l)     −0.015   0.004   0.58              0.44, 0.76   \<0.0001
  HDL cholesterol (0.36 mmol/l)       −0.009   0.009   0.87              0.67, 1.14   0.327
  Triglycerides^b^ (1.1 times)        −0.019   0.257   0.98              0.59, 1.62   0.940
  AST (5 units/l)                     −0.007   0.031   0.96              0.69, 1.33   0.813
  ALT (3 units/l)                     −0.033   0.051   0.89              0.63, 1.26   0.508
  γ-GTP^b^ (2.2 times)                0.123    0.181   1.13              0.79, 1.61   0.496
  Smoking                             0.828    0.288   2.29              1.30, 4.03   0.004
  Alcohol                             0.422    0.287   1.53              0.87, 2.68   0.141
  Antihypertensive medication         −0.127   0.347   0.88              0.45, 1.74   0.714
  Antihyperlipidemic medication       0.621    0.467   1.86              0.75, 4.66   0.183
  Antidiabetic medication             0.951    0.517   2.59              0.94, 7.15   0.066

Abbreviations: SE, standard error; HGF, hepatocyte growth factor; BP, blood pressure, HDL, high-density lipoprotein, AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase.

^a^Weight (kg)/height (m)^2^.

^b^These variables are shown in the original scale after analysis using log (natural)-transformed values. These values indicate hazard ratios per times increase.

^c^Hazard ratio per 1-increment increase in variable.

Using the significant factors shown in Tables [3](#tbl03){ref-type="table"} and [4](#tbl04){ref-type="table"}, we performed multivariate proportional hazards regression analysis (Tables [5](#tbl05){ref-type="table"} and [6](#tbl06){ref-type="table"}). Age, systolic blood pressure, HGF, albumin (inversely), smoking, and creatinine remained significantly associated with all-cause death (Table [5](#tbl05){ref-type="table"}): the HRs by HGF quartile after adjustment for confounding factors were 1.15 (95% CI, 0.68--1.93) for Q2, 1.49 (0.91--2.44) for Q3, and 1.77 (1.10--2.97) for Q4. For cancer death, age, HGF, and total cholesterol (inversely) remained significant (Table [6](#tbl06){ref-type="table"}): after adjustment for confounding factors, the HRs by HGF quartile were 1.22 (95% CI, 0.53--2.83) for Q2, 1.19 (0.50--2.83) for Q3, and 2.21 (1.03--4.76) for Q4.

###### Multivariate proportional hazards regression analysis of all-cause death

  Dependent variable (increment)      Beta     SE      Hazard ratio^c^   95% CI       *P* value
  ----------------------------------- -------- ------- ----------------- ------------ -----------
  Age (10 years)                      0.088    0.013   2.53              1.90, 3.37   \<0.0001
  Systolic BP (20 mm Hg)              0.013    0.005   1.32              1.08, 1.63   0.007
  HGF (0.09 ng/ml)                    2.593    1.006   1.27              1.06, 1.52   0.009
  Albumin (2 g/l)                     −1.019   0.460   0.77              0.61, 0.97   0.026
  Smoking                             0.654    0.298   1.93              1.07, 3.45   0.028
  Creatinine (16.4 µmol/l)            0.706    0.311   2.03              1.10, 5.73   0.033
  γ-GTP^b^ (2.2 times)                0.072    0.110   1.19              0.96, 1.48   0.109
  C-reactive protein^b^ (1.8 times)   0.160    0.106   1.17              0.96, 1.44   0.128
  Hypertensive medication             −0.382   0.263   0.68              0.41, 1.14   0.146
  Blood urea nitrogen (1.4 mmol/l)    0.038    0.027   1.17              0.94, 1.46   0.161
  HbA1c (0.7%)                        0.133    0.114   1.11              0.93, 1.32   0.242
  Total cholesterol (0.87 mmol/l)     −0.002   0.003   0.91              0.71, 1.17   0.455
  Uric acid (59.4 µmol/l)             0.040    0.086   1.06              0.84, 1.34   0.639
  Male sex                            0.107    0.296   1.11              0.62, 1.99   0.716
  Body mass index^a^ (3 kg/m^2^)      0.003    0.038   1.01              0.80, 1.28   0.924

Abbreviations: HGF, hepatocyte growth factor; SE, standard error; BP, blood pressure; γ-GTP, γ-glutamyl transpeptidase.

^a^Weight (kg)/height (m)^2^.

^b^These variables are shown in the original scale after analysis using log (natural)-transformed values. These values indicate hazard ratios per times increase.

^c^Hazard ratio per 1-increment increase in variable.

###### Multivariate proportional hazards regression analysis of cancer death

  Dependent variable (increment)     Beta     SE      Hazard ratio^a^   95% CI       *P* value
  ---------------------------------- -------- ------- ----------------- ------------ -----------
  Age (10 years)                     0.065    0.017   2.00              1.39, 2.87   \<0.001
  HGF (0.09 ng/ml)                   2.929    1.267   1.31              1.04, 1.65   0.020
  Total cholesterol (0.87 mmol/l)    −0.010   0.005   0.68              0.48, 0.97   0.034
  Blood urea nitrogen (1.4 mmol/l)   0.059    0.034   1.28              0.97, 1.68   0.082
  HbA1c (0.7%)                       0.193    0.123   1.16              0.96, 1.41   0.116
  Male sex                           0.547    0.408   1.73              0.78, 3.85   0.180
  Albumin (2 g/l)                    −0.787   0.630   0.82              0.59, 1.12   0.211
  Smoking                            0.472    0.383   1.60              0.76, 3.40   0.217
  Creatinine (16.4 µmol/l)           0.506    0.567   1.66              0.55, 5.04   0.371
  Systolic BP (20 mm Hg)             0.003    0.007   1.08              0.81, 1.45   0.608

Abbreviations: HGF, hepatocyte growth factor; SE, standard error; BP, blood pressure.

^a^Hazard ratio per 1-increment increase in variable.

There was no significant association between HGF and cerebrocardiovascular death (data not shown).

DISCUSSION
==========

We investigated whether plasma HGF predicted cancer death among a population of Japanese adults. Our results showed that plasma HGF level was predictive of both all-cause death and cancer death.

We made every effort in this prospective study to ascertain cause of death, and the death rates among this population were comparable to those of the Japanese general population.^[@r19]^ Multivariate proportional hazards regression analysis revealed that age, systolic blood pressure, HGF, albumin (inversely), smoking, and creatinine were independently associated with all-cause death (Table [5](#tbl05){ref-type="table"}). Age, blood pressure, and smoking are known causes of cerebrocardiovascular death. Thus, it is feasible that these factors contributed to all-cause death in this population. However, the number of deaths from cerebrocardiovascular disease was too small to analyze, and we were thus unable to identify the factors responsible for cerebrocardiovascular death in this study. In addition to the above-mentioned factors, low albumin and HGF were significant predictors of all-cause death (Table [5](#tbl05){ref-type="table"}). Low albumin may indicate poor nutritional status. The predictive power of HGF was comparable to that of systolic blood pressure (Table [5](#tbl05){ref-type="table"}). At present, it is unclear why HGF was a significant predictor of all-cause death.

We investigated whether HGF was a predictor of cancer death in this apparently healthy population because cancer is the most common cause of death in this population and because HGF level was found to be a predictor of death in patients with cancer.^[@r08]--[@r13]^ Multivariate proportional hazards regression analysis revealed that age, HGF, and cholesterol (inversely) were predictors of cancer death. Although baseline HGF was associated with cholesterol (inversely) and some other factors, as shown in Table [1](#tbl01){ref-type="table"}, the data in Table [6](#tbl06){ref-type="table"} show that HGF was a significant independent factor for cancer death, which indicates that HGF is a predictor for cancer death in apparently healthy community-dwelling Japanese adults.

The pathophysiologic mechanisms for the association between HGF and cancer death in this population were not investigated in this epidemiologic study. Because we excluded patients with history of cancer at baseline, it is natural to assume that the remaining study participants developed cancer during follow-up. To confirm this, we divided cancer deaths into those that occurred during the first 5 years of follow-up and those that occurred in the second 5 years of follow-up. There were 30 cancer deaths during the first 5 years and 31 during the second 5 years. As mentioned above, serum HGF is elevated in individuals with cancer.^[@r07]--[@r11]^ HGF is released from cancer cells^[@r11],[@r12]^ and stimulates not only tumor cell invasion but also neovascularization as a potent endothelial growth factor.^[@r13],[@r20]--[@r23]^ If participants who died within 5 years had subclinical cancer at baseline, they might have had higher baseline HGF levels. However, we found that baseline HGF was similar in the early and late study periods among participants who died of cancer. Thus, the increase in the risk of cancer death associated with high HGF was not due to the presence of subclinical cancer. It is possible that participants with high baseline HGF levels experienced rapid growth and spread of cancer once they developed cancer. However, this hypothesis cannot be confirmed in an observational study.

A strength of the present study is that it is the first prospective cohort study to show that HGF is a predictor of cancer death in apparently healthy adults. Moreover, the follow-up rate was high (92.9%).

A limitation of this study is that, because of the relatively small number of cancer deaths, we were unable to investigate the association between HGF and particular malignancies. Second, the cancer endpoint was not incidence but mortality. Third, the association between HGF and cancer death might be confounded by several factors. However, this association remained significant after adjustment for confounders.

In conclusion, serum HGF was a predictor of cancer death in an apparently healthy community-dwelling Japanese population. Our findings suggest that serum HGF may be a predictive marker for cancer death in the general population.
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[^1]: List of abbreviations: HGF, hepatocyte growth factor; BMI, body mass index; BUN, blood urea nitrogen; CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GTP, γ-glutamyl transpeptidase.
